Boston Scientific CorporationBSXNYSE
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank38
Year-over-Year Change
Year-over-year free cash flow growth rate
Percentile
P38
Within normal range
vs 5Y Ago
-3x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -12.82% |
| Q3 2025 | 6.02% |
| Q2 2025 | 209.60% |
| Q1 2025 | -69.56% |
| Q4 2024 | 66.62% |
| Q3 2024 | 6.08% |
| Q2 2024 | 912.35% |
| Q1 2024 | -111.74% |
| Q4 2023 | 40.24% |
| Q3 2023 | 8.85% |
| Q2 2023 | 555.07% |
| Q1 2023 | -88.63% |
| Q4 2022 | 103.69% |
| Q3 2022 | 47.52% |
| Q2 2022 | 206.88% |
| Q1 2022 | -189.15% |
| Q4 2021 | -40.78% |
| Q3 2021 | -33.33% |
| Q2 2021 | 156.94% |
| Q1 2021 | -59.34% |
| Q4 2020 | 4.26% |
| Q3 2020 | 183.33% |
| Q2 2020 | 197.21% |
| Q1 2020 | -135.38% |
| Q4 2019 | 40.95% |
| Q3 2019 | 214.91% |
| Q2 2019 | -55.98% |
| Q1 2019 | 397.70% |
| Q4 2018 | -122.37% |
| Q3 2018 | 180.04% |
| Q2 2018 | -1720.00% |
| Q1 2018 | -96.22% |
| Q4 2017 | 126.57% |
| Q3 2017 | 66.67% |
| Q2 2017 | 242.86% |
| Q1 2017 | -149.16% |
| Q4 2016 | 393.14% |
| Q3 2016 | -129.74% |
| Q2 2016 | 512.50% |
| Q1 2016 | -77.05% |